Lee Ann Steadman
SVP
Expertise:
Lee Ann brings with her more than 15 years of pharmaceutical and medical device experience working with companies such as Sanofi, Lash Group and UBC, Inc. Lee Ann uses her expertise to support the full life cycle of a product.
With her knowledge in patient and provider services and channel strategy, Lee Ann has launched more than 30 patient and provider support programs including reimbursement, distribution, financial assistance programs, call centers, sites of care and clinical trial support services across numerous therapeutic classes. Her experience includes support of oncology, rheumatology, neurology, cardiology and rare diseases.
Lee Ann earned a BS degree in Psychology and minor in Business from Kansas State University.
Articles by Lee Ann Steadman
Navigating Pharmaceutical Success: Harnessing Data Analytics and Predictive Modeling
In the fast-paced world of pharmaceuticals, where market forecasting and regulatory compliance are paramount, data-driven insights can make all the difference. Discover how EVERSANA’s Specialty Consulting team excels in crafting tailored predictive modeling solutions for pharmaceutical manufacturers of all sizes. With a comprehensive understanding of the challenges inherent in product commercialization, we offer strategic advantages that pave the way for long-term success. Delve deeper into how data analytics and predictive modeling are vital decision-making tools for success. From optimizing patient support programs to designing affordability initiatives, our solutions empower manufacturers to navigate complexities with confidence. Traditional forecasting methods often fall short, but with EVERSANA’s predictive modeling solutions, manufacturers can simulate […]
Maximizing Product Launch Success: The Importance of Conducting Comprehensive Business Simulation Exercises
Product launch preparedness is a vital aspect of bringing new products to market, particularly in the pharmaceutical industry where patients’ health and well-being can be impacted, in addition to the brand’s success and overall reputation. As 66% of new products fail to meet launch expectations, it is important for manufacturers to prioritize pre-launch preparedness and understand what potential costly failings could lie ahead, and how to mitigate them. To address key challenges that often lead to products’ disappointing performance, and cause manufacturers to spend millions of dollars addressing issues that could and should have been caught prior to launch, EVERSANA’s business simulation exercise serves as a valuable investment that helps […]
Left-Right-Left: The Latest in Pharma-Payer Ping Pong
Biopharmaceutical companies have offered financial assistance for commercially covered patients’ out-of-pocket (OOP) cost sharing for 20+ years. However, in the ongoing evolution of controlling versus encouraging patient access to specific drugs, payers and biopharma also have a long history of one-upmanship. Are pharma motivations for offering copay assistance centered on the patient, their own bottom line, or some mix of both? And regardless of intent, should payers let affected members’ deductibles or even maximum OOP costs reach their thresholds through external dollars? In this latest NAVLIN Insights article, learn more about how each are trying to balance patient access with financial demands – and what to expect in the future. Complete […]
Solving the Wastage Challenge Through Predictive Analytics and Modeling
“Solving the Wastage Challenge Through Predictive Analytics and Modeling,” authored by John Chatas, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores how legislative changes like the Wastage Reduction Act are driving pharma companies to find innovative ways to minimize product wastage & avoid costly fines. EVERSANA’s #SpecialtyConsulting supports pharma companies through modeling and predictive forecasting to avoid excessive #productwastage and high-priced penalties. Learn more about how our experts help manufacturers pinpoint their products’ “sweet spot” for practical and economical storing and administering by downloading the article now. Complete the form below to download the full article.
Elevating Field Reimbursement Manager Performance through Insights & Comparative Data
“Elevating Field Reimbursement Managers’ Performance through Customer-based Insights and Comparative Data,” authored by David Frey, Principal, Specialty Consulting, EVERSANA and Lee Ann Steadman, Senior Vice President, Specialty Consulting, EVERSANA explores the evolving role of Field Reimbursement Managers (FRMs) and how it has evolved to become a critical role for pharmaceutical manufacturers. This article also reviews the importance of securing and applying actionable feedback from customers in order to effectively enhance patient access, affordability and patient adherence. In the absence of this crucial role, patients may suffer and pharma companies may be outpaced by their competitors. Learn how EVERSANA’s FRM satisfaction research obtains comparative performance data through customizable surveys to inform […]
THINK BEYOND THE THERAPY: Demystifying the Complexities of Cell and Gene Therapy Commercialization
While much attention has been given to the novel science behind cell and gene therapies, ultimately the success of every precision medicine starts and ends with the patient. Whether coordinating a cell or gene therapy clinical trial or product launch, even the best-planned efforts can be derailed without a clear strategy for facilitating access to the therapy and supporting patients through the treatment journey. This is true for almost every specialty product, but it is especially important for cell and gene therapies, given the high cost and complexity of administering these innovative new therapies. On the surface, the commercialization process for cell and gene therapies may seem simple. However, many […]
Are You Tracking the Performance and Satisfaction Ratings of Your Patient Services?
The types of services patients need for support change and fluctuate over time, particularly as a product moves through its lifecycle. The patient services necessary to drive access, affordability and adherence to your product in the launch phase can be markedly different from the patient services that accomplish the same goals at later stages of your product’s lifecycle. This makes it critical that manufacturers continually check to ensure they are still providing relevant and differentiating services to all stakeholders throughout all stages – from diagnosis to therapy initiation and adherence. It should also be noted that providing the right services at the right time is not enough. You also need […]
Optimizing the Performance of a PSP and Improving Outcomes For All Stakeholders
Patient Support Programs (PSP) have been proven to improve clinical and patient outcomes and help manage patient out-of-pocket cost and prescribed use. Particularly for specialty drugs, the services provided under the PSP umbrella not only help remove barriers to patient access, they provide healthcare providers (HCPs) with tools they can use to help patients better manage their disease. The challenge has been with ensuring a PSP is evolving and maturing in a way that aligns with patient and stakeholder needs as well as the product’s lifecycle. Click here to download the white paper.